Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
Open Access
- 17 June 2008
- journal article
- research article
- Published by Springer Nature in International Journal of Obesity
- Vol. 32 (8) , 1201-1210
Abstract
Objective: To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats. Design: DIO rats were intraperitoneally injected with a single dose of amylin (10 μg kg−1) and/or phentermine (1 mg kg−1) or chronically infused with amylin (100 μg kg−1 d−1) or vehicle with or without phentermine (0.5–10 mg kg−1 d−1) or sibutramine (3 mg kg−1 d−1) using two surgically implanted subcutaneous osmotic mini-pumps. Measurements: Twenty-four hour food intake, locomotor activity and components of meal microstructure (meal size, latency, duration and intermeal interval) were measured following acute administration (amylin, phentermine or amylin+phentermine). Body weight and composition (for amylin and/or sibutramine or phentermine) and metabolism-related gene mRNA expression in the liver (fatty acid synthase, stearoyl-CoA desaturase-1 and carnitine palmitoyltransferase-1) and brown fat (β-adrenergic receptors and uncoupling protein-1) were measured (for amylin and/or phentermine) after sustained infusion (2 weeks). Results: Acute co-administration of amylin (10 μg kg−1) and phentermine (1 mg kg−1) reduced acute food intake (up to 19 h) more than either monotherapy. In two studies, sustained subcutaneous infusion of amylin for 2 weeks decreased cumulative food intake (22%) and vehicle-corrected body weight gain (∼4–8%). Phentermine's anorexigenic (10–17%) and weight-reducing effects (∼0–5%) were only evident at the highest dose tested (10 mg kg−1 d−1). Combination of amylin (100 μg kg−1 d−1) and phentermine reduced food intake (30–43%), body weight (8–12%) and adiposity to a greater extent than either monotherapy. Amylin prevented phentermine-induced reductions in UCP-1 mRNA in brown adipose tissue. When amylin+sibutramine were infused, mathematically additive decreases in food intake (up to 45%) and body weight (up to 12%) were evident. Similar to amylin+phentermine treatment, amylin+sibutramine mediated weight loss was attributable to significant reductions in fat mass. Conclusions: Combined treatment of DIO rats with the pancreatic β-cell hormone amylin and phentermine or sibutramine resulted in additive anorexigenic, weight- and fat-reducing effects.Keywords
This publication has 38 references indexed in Scilit:
- Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weightAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research studyAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation StudyThe Journal of Clinical Endocrinology & Metabolism, 2007
- Peroxisome Proliferator–Activated Receptor-γ Regulates Expression of PDX-1 and NKX6.1 in INS-1 CellsDiabetes, 2007
- Antiobesity Effects of the β-Cell Hormone Amylin in Diet-Induced Obese Rats: Effects on Food Intake, Body Weight, Composition, Energy Expenditure, and Gene ExpressionEndocrinology, 2006
- Central nervous system control of food intake and body weightNature, 2006
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetesDiabetologia, 2005
- The Gut and Energy Balance: Visceral Allies in the Obesity WarsScience, 2005
- The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned ratsInternational Journal of Obesity, 2001
- Amylin: A Novel Action in the Brain to Reduce Body WeightEndocrinology, 2000